Replies to post #398332 on Anavex Life Sciences Corp (AVXL)

[crescentmotor]

There are still no answer to this conundrum [confusion over endpoints and other incomplete data]

That conundrum is one important reason AVXL's stock price sits at an unbelievable low price of $11 or so in the face of a company that announced a totally successful advanced AD trial. Legitimate questions obviously exist concerning the data. An even more important conundrum is that, without complete and convincing data, there can be no regulatory path to approval.

"Publishing that deep analysis belongs with little doubt in the new long term catalyst Anavex bucket."

There had better be a lot of further basic analysis in the short-term AVXL bucket. Unless and until AVXL can put together a comprehensive and convincing data package, it will not be in a position to meet with regulatory authorities to establish a path forward. That package needs to come together within the next couple of months, in my opinion, so that meetings can be held with regulators by third quarter 2023.

[bas2020]

I only offered a possible reason why the company hasn't released the detailed data or the n for the OR (i.e. one trial site data late arriving, not included). They still have plenty of data to make a successful trial claim... and will wait until all data is available and analyzed before releasing the full data results with subgroups.

Unlike some here with questionable accusations, most here trust Anavex & Missling when they claim that ALL ENDPOINTS WERE MET, because a reputable company wouldn't be so irresponsible to make false claims.